They showed that ISRIB treatment alleviated Aβ [1-42]-induced cognitive impairment, reduced the pNF-κB/NF-κB ratio, and downregulated pro-inflammatory proteins such as interleukin-1 beta (IL-1β), cyclooxygenase-2, and tumor necrosis factor-alpha (TNF-α), while simultaneously upregulating anti-inflammatory cytokines IL-4 and IL-10 [64]. The gene discussed is TNF; the disease is Cognitive impairment.